RTW Investments, LP and its Managing Partner Roderick Wong filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 5,905,426 shares of Solid Biosciences Inc. common stock as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 814,229 Class A Ordinary Shares of Harvard Ave Acquisition Corporation as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of ordinary shares of LaFayette Acquisition Corp. as of September 30, 2026.
Highbridge Capital Management, LLC filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing that it holds zero ordinary shares of Peace Acquisition Corp. as of September 30, 2026.
Highbridge Capital Management, LLC filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,454,400 shares of INmune Bio, Inc. common stock issuable upon exercise of warrants held by Highbridge-managed funds.
Highbridge Capital Management, LLC filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 11,010,766 shares of Sharplink, Inc. common stock as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, reporting beneficial ownership of 654,922 Class A Ordinary Shares of Lake Superior Acquisition Corp as of September 30, 2026.
RTW Investments, LP and Roderick Wong filed Amendment No. 8 to Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 6,537,475 shares of Stoke Therapeutics, Inc. common stock as of September 30, 2026.
Highbridge Capital Management, LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,105,223 Class A Ordinary Shares of Lionheart Holdings as of September 30, 2026.
RTW Investments, LP and its Managing Partner Roderick Wong, M.D. filed Amendment No. 4 to their beneficial ownership statement covering Tenax Therapeutics, Inc. common stock, disclosing a position of zero shares as of September 30, 2026, with the filing submitted on November 16, 2026.